GRPR-targeted Protein Contrast Agents for Molecular Imaging of Receptor Expression in Cancers by MRI

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Pu, Fan ^a   Qiao, Jingjuan ^a   Xue, Shenghui ^a   Yang, Hua ^b   Patel, Anvi ^a   Wei, Lixia ^a   Hekmatyar, Khan ^c   Salarian, Mani ^a   Grossniklaus, Hans E ^b   Liu, Zhi Ren ^a   Yang, Jenny J ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BOMBESIN RECEPTOR; CONTRAST MEDIUM; LIGAND; PROTEIN BINDING;

ANIMAL; BINDING SITE; CHEMISTRY; CONFORMATION; DISEASE MODEL; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; MOLECULAR IMAGING; MOLECULAR MODEL; MOUSE; NEOPLASMS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES; RAT; TISSUE DISTRIBUTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BINDING SITES; BIOMARKERS; CELL LINE, TUMOR; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HETEROGRAFTS; HUMANS; LIGANDS; MAGNETIC RESONANCE IMAGING; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR IMAGING; NEOPLASMS; PROTEIN BINDING; RATS; RECEPTORS, BOMBESIN; TISSUE DISTRIBUTION;

EID: 84947556079     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16214     Document Type: Article

References (64)

1. Reile, H., Armatis, P. E., Schally, A. V. Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells. Prostate 25, 29-38 (1994).
2. Reubi, J. C., Wenger, S., Schmuckli-Maurer, J., Schaer, J. C., Gugger, M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14). Clin Cancer Res 8, 1139-1146 (2002).
3. Gugger, M., Reubi, J. C. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. The American journal of pathology 155, 2067-2076 (1999).
4. Markwalder, R., Reubi, J. C. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer research 59, 1152-1159 (1999).
5. Jensen, R. T., Battey, J. F., Spindel, E. R., Benya, R. V. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacological reviews 60, 1-42 (2008).
6. Achilefu, S. et al. Synthesis, in vitro receptor binding, and in vivo evaluation of fluorescein and carbocyanine peptide-based optical contrast agents. Journal of medicinal chemistry 45, 2003-2015 (2002).
7. Cai, Q. Y. et al. Near-infrared fluorescence imaging of gastrin releasing peptide receptor targeting in prostate cancer lymph node metastases. Prostate 73, 842-854 (2013).
8. Ma, L. et al. In vitro and in vivo evaluation of Alexa Fluor 680-bombesin[7-14]NH2 peptide conjugate, a high-affinity fluorescent probe with high selectivity for the gastrin-releasing peptide receptor. Molecular imaging 6, 171-180 (2007).
9. Young, S. H., Rozengurt, E. Qdot nanocrystal conjugates conjugated to bombesin or ANG II label the cognate G proteincoupled receptor in living cells. American journal of physiology. Cell physiology 290, C728-732 (2006).
10. Chang, Y. J. et al. Molecular imaging and therapeutic efficacy of 188Re-(DXR)-liposome-BBN in AR42J pancreatic tumorbearing mice. Oncology reports 28, 1736-1742 (2012).
11. Liu, Y. et al. A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 54, 2132-2138 (2013).
12. Kahkonen, E. et al. In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. Clin Cancer Res 19, 5434-5443 (2013).
13. Mather, S. J. et al. GRP receptor imaging of prostate cancer using [(99m)Tc]Demobesin 4: a first-in-man study. Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 16, 888-895 (2014).
14. Van de Wiele, C. et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. European journal of nuclear medicine 27, 1694-1699 (2000).
15. Scopinaro, F. et al. 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. European journal of nuclear medicine and molecular imaging 30, 1378-1382 (2003).
16. Bodei, L. et al. 177Lu-AMBA Bombesin analogue in hormone refractory prostate cancer patients: a phase I escalation study with single-cycle administrations. European journal of nuclear medicine and molecular imaging 34, S221 (2007).
17. Hofmann, M. et al. Feasibility of Ga-68-DOTABOM PET in prostate carcinoma patients. In European journal of nuclear medicine and molecular imaging, Vol. 31 S253-S253 (SPRINGER 233 SPRING STREET, NEW YORK, NY 10013 USA, 2004).
18. Hricak, H. MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer. The British journal of radiology 78 Spec No 2, S103-111 (2005).
19. Winter, P. M. et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer research 63, 5838-5843 (2003).
20. Marckmann, P. et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. Journal of the American Society of Nephrology : JASN 17, 2359-2362 (2006).
21. Yang, J. J. et al. Rational design of protein-based MRI contrast agents. Journal of the American Chemical Society 130, 9260-9267 (2008).
22. Xue, S., Qiao, J., Pu, F., Cameron, M., Yang, J. J. Design of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkers. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology 5, 163-179 (2013).
23. Qiao, J. et al. Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents. Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry 19, 259-270 (2014).
24. Xue, S. et al. Design of ProCAs (protein-based Gd(3+ ) MRI contrast agents) with high dose efficiency and capability for molecular imaging of cancer biomarkers. Medicinal research reviews 34, 1070-1099 (2014).
25. Ye, Y., Lee, H. W., Yang, W., Shealy, S., Yang, J. J. Probing site-specific calmodulin calcium and lanthanide affinity by grafting. Journal of the American Chemical Society 127, 3743-3750 (2005).
26. Wei, L. et al. Protein-based MRI contrast agents for molecular imaging of prostate cancer. Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 13, 416-423 (2011).
27. Zhou, Y., Xue, S., Chen, Y., Yang, J. J. Probing Ca2+-binding capability of viral proteins with the EF-hand motif by grafting approach. Methods in molecular biology 963, 37-53 (2013).
28. Corjay, M. H. et al. Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells. The Journal of biological chemistry 266, 18771-18779 (1991).
29. Lantry, L. E. et al. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 47, 1144-1152 (2006).
30. Qiao, J. et al. HER2 targeted molecular MR imaging using a de novo designed protein contrast agent. PloS one 6, e18103 (2011).
31. Allison, M. The HER2 testing conundrum. Nat Biotechnol 28, 117-119 (2010).
32. Caravan, P. et al. Collagen-targeted MRI contrast agent for molecular imaging of fibrosis. Angew Chem Int Ed Engl 46, 8171-8173 (2007).
33. Polasek, M. et al. Molecular MR Imaging of Liver Fibrosis: A Feasibility Study using Rat and Mouse Models. J Hepatol 57, 549-555 (2012).
34. Spuentrup, E. et al. Molecular magnetic resonance imaging of myocardial perfusion with EP-3600, a collagen-specific contrast agent: initial feasibility study in a swine model. Circulation 119, 1768-1775 (2009).
35. Burtea, C. et al. Magnetic resonance molecular imaging of vascular cell adhesion molecule-1 expression in inflammatory lesions using a peptide-vectorized paramagnetic imaging probe. Journal of medicinal chemistry 52, 4725-4742 (2009).
36. De Leon-Rodriguez, L. M. et al. MRI detection of VEGFR2 in vivo using a low molecular weight peptoid-(Gd)8-dendron for targeting. Journal of the American Chemical Society 132, 12829-12831 (2010).
37. Zhu, W., Okollie, B., Bhujwalla, Z. M., Artemov, D. PAMAM dendrimer-based contrast agents for MR imaging of Her-2/neu receptors by a three-step pretargeting approach. Magn Reson Med 59, 679-685 (2008).
38. Flacke, S. et al. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 104, 1280-1285 (2001).
39. Cheng, Z., Thorek, D. L., Tsourkas, A. Gadolinium-conjugated dendrimer nanoclusters as a tumor-targeted T1 magnetic resonance imaging contrast agent. Angew Chem Int Ed Engl 49, 346-350 (2010).
40. Ouimet, T. et al. Molecular and cellular targets of the MRI contrast agent P947 for atherosclerosis imaging. Mol Pharm 9, 850-861 (2012).
41. Sun, Y. G., Chen, Z. F. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 448, 700-703 (2007).
42. Patel, O., Shulkes, A., Baldwin, G. S. Gastrin-releasing peptide and cancer. Biochimica et biophysica acta 1766, 23-41 (2006).
43. Asti, M. et al. Influence of different chelators on the radiochemical properties of a 68-Gallium labelled bombesin analogue. Nuclear medicine and biology 41, 24-35 (2014).
44. Varasteh, Z. et al. The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin. Molecules 19, 10455-10472 (2014).
45. Pan, D. et al. PET imaging of prostate tumors with 18F-Al-NOTA-MATBBN. Contrast media & molecular imaging 9, 342-348 (2014).
46. Varasteh, Z. et al. In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging. PloS one 8, e81932 (2013).
47. Jimenez-Mancilla, N. et al. Multifunctional targeted therapy system based on (99m) Tc/(177) Lu-labeled gold nanoparticles-Tat(49-57)-Lys(3)-bombesin internalized in nuclei of prostate cancer cells. Journal of labelled compounds & radiopharmaceuticals 56, 663-671 (2013).
48. Zhou, Z. et al. Synthesis and in vitro and in vivo evaluation of hypoxia-enhanced 111In-bombesin conjugates for prostate cancer imaging. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 54, 1605-1612 (2013).
49. Fulton, D. A. et al. Efficient relaxivity enhancement in dendritic gadolinium complexes: effective motional coupling in medium molecular weight conjugates. Chemical communications, 474-476 (2005).
50. Fulton, D. A. et al. Glycoconjugates of gadolinium complexes for MRI applications. Chemical communications, 1064-1066 (2006).
51. Caravan, P., Ellison, J. J., McMurry, T. J., Lauffer, R. B. Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. Chemical reviews 99, 2293-2352 (1999).
52. Uehara, H. et al. The molecular basis for high affinity of a universal ligand for human bombesin receptor (BnR) family members. Biochemical pharmacology 84, 936-948 (2012).
53. Mantey, S. A. et al. Rational design of a peptide agonist that interacts selectively with the orphan receptor, bombesin receptor subtype 3. The Journal of biological chemistry 276, 9219-9229 (2001).
54. Wang, L. H. et al. Activation of neuromedin B-preferring bombesin receptors on rat glioblastoma C-6 cells increases cellular Ca2+ and phosphoinositides. The Biochemical journal 286 ( Pt 2), 641-648 (1992).
55. Shrivastava, A. et al. A high-affinity near-infrared fluorescent probe to target bombesin receptors. Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 16, 661-669 (2014).
56. Tweedle, M. F. Peptide-targeted diagnostics and radiotherapeutics. Accounts of chemical research 42, 958-968 (2009).
57. Fang, J., Nakamura, H., Maeda, H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Advanced drug delivery reviews 63, 136-151 (2011).
58. Dreher, M. R. et al. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. Journal of the National Cancer Institute 98, 335-344 (2006).
59. Xue, S. et al. Protein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer imaging. Proceedings of the National Academy of Sciences 112, 6607-6612 (2015).
60. Zhang, C. et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer research 67, 1555-1562 (2007).
61. Schmieder, A. H. et al. Molecular MR imaging of neovascular progression in the Vx2 tumor with alphavbeta3-targeted paramagnetic nanoparticles. Radiology 268, 470-480 (2013).
62. Cai, W., Chen, X. Multimodality molecular imaging of tumor angiogenesis. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 49 Suppl 2, 113S-128S (2008).
63. Mahmood, U., Tung, C. H., Bogdanov, A. Jr., Weissleder, R. Near-infrared optical imaging of protease activity for tumor detection. Radiology 213, 866-870 (1999).
64. Delli Castelli, D., Ferrauto, G., Cutrin, J. C., Terreno, E., Aime, S. In vivo maps of extracellular pH in murine melanoma by CEST-MRI. Magn Reson Med 71, 326-332 (2014).